 | • レポートコード：MRC23Q36027 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の胃腸市場について調査・分析し、世界の胃腸市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（医療用胃腸薬、一般用胃腸薬）、用途別セグメント分析（慢性胃炎、機能性ディスペプシア、消化性潰瘍、急性胃腸炎、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、AstraZenec、Sanofi、Bayer、Pfizer、GlaxoSmithKline、Teva、Zeria（Tillotts）、Perrigo、Boehringer Ingelheim、Purdue Pharma、C.B. Fleet、Abbott、Jiangzhong、Xian-Janssenなどが含まれています。世界の胃腸市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、胃腸市場規模を推定する際に考慮しました。本レポートは、胃腸の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、胃腸に関するビジネス上の意思決定に役立てることを目的としています。 ・胃腸市場の概要 - 胃腸のタイプ別セグメント - 世界の胃腸市場規模：タイプ別分析（医療用胃腸薬、一般用胃腸薬） - 胃腸の用途別セグメント - 世界の胃腸市場規模：用途別分析（慢性胃炎、機能性ディスペプシア、消化性潰瘍、急性胃腸炎、その他） - 世界の胃腸市場規模予測（2018年-2029年） ・胃腸市場の成長トレンド - 胃腸の地域別市場規模（2018年-2029年） - 胃腸市場ダイナミクス - 胃腸の業界動向 - 胃腸市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：医療用胃腸薬、一般用胃腸薬 - 世界の胃腸のタイプ別市場規模（2018年-2023年） - 世界の胃腸のタイプ別市場規模（2024年-2029年） ・用途別セグメント：慢性胃炎、機能性ディスペプシア、消化性潰瘍、急性胃腸炎、その他 - 世界の胃腸の用途別市場規模（2018年-2023年） - 世界の胃腸の用途別市場規模（2024年-2029年） ・胃腸の地域別市場規模 - 北米の胃腸市場規模（2018年-2029年） - アメリカの胃腸市場規模（2018年-2029年） - ヨーロッパの胃腸市場規模（2018年-2029年） - アジア太平洋の胃腸市場規模（2018年-2029年） - 中国の胃腸市場規模（2018年-2029年） - 日本の胃腸市場規模（2018年-2029年） - 韓国の胃腸市場規模（2018年-2029年） - インドの胃腸市場規模（2018年-2029年） - オーストラリアの胃腸市場規模（2018年-2029年） - 中南米の胃腸市場規模（2018年-2029年） - 中東・アフリカの胃腸市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 AstraZenec、Sanofi、Bayer、Pfizer、GlaxoSmithKline、Teva、Zeria（Tillotts）、Perrigo、Boehringer Ingelheim、Purdue Pharma、C.B. Fleet、Abbott、Jiangzhong、Xian-Janssen ・アナリストの観点/結論 ・調査方法とデータソース |
Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn’s disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
Highlights
The global Gastrointestinal market was valued at US$ 35990 million in 2022 and is anticipated to reach US$ 43730 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Gastrointestinal key players include AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, etc. Global top five manufacturers hold a share over 25%.
Europe is the largest market, with a share about 45%, followed by Asia, and North America, both have a share over 45 percent.
In terms of product, Prescription Gastrointestinal Drug is the largest segment, with a share over 80%. And in terms of application, the largest application is Chronic Gastritis, followed by Peptic Ulcer, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal.
The Gastrointestinal market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Gastrointestinal market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AstraZenec
Sanofi
Bayer
Pfizer
GlaxoSmithKline
Teva
Zeria（Tillotts）
Perrigo
Boehringer Ingelheim
Purdue Pharma
C.B. Fleet
Abbott
Jiangzhong
Xian-Janssen
Segment by Type
Prescription Gastrointestinal Drug
OTC Gastrointestinal Drug
Segment by Application
Chronic Gastritis
Functional Dyspepsia
Peptic Ulcer
Acute Gastroenteritis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastrointestinal Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Prescription Gastrointestinal Drug
1.2.3 OTC Gastrointestinal Drug
1.3 Market by Application
1.3.1 Global Gastrointestinal Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Chronic Gastritis
1.3.3 Functional Dyspepsia
1.3.4 Peptic Ulcer
1.3.5 Acute Gastroenteritis
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastrointestinal Market Perspective (2018-2029)
2.2 Gastrointestinal Growth Trends by Region
2.2.1 Global Gastrointestinal Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gastrointestinal Historic Market Size by Region (2018-2023)
2.2.3 Gastrointestinal Forecasted Market Size by Region (2024-2029)
2.3 Gastrointestinal Market Dynamics
2.3.1 Gastrointestinal Industry Trends
2.3.2 Gastrointestinal Market Drivers
2.3.3 Gastrointestinal Market Challenges
2.3.4 Gastrointestinal Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastrointestinal Players by Revenue
3.1.1 Global Top Gastrointestinal Players by Revenue (2018-2023)
3.1.2 Global Gastrointestinal Revenue Market Share by Players (2018-2023)
3.2 Global Gastrointestinal Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gastrointestinal Revenue
3.4 Global Gastrointestinal Market Concentration Ratio
3.4.1 Global Gastrointestinal Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Revenue in 2022
3.5 Gastrointestinal Key Players Head office and Area Served
3.6 Key Players Gastrointestinal Product Solution and Service
3.7 Date of Enter into Gastrointestinal Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastrointestinal Breakdown Data by Type
4.1 Global Gastrointestinal Historic Market Size by Type (2018-2023)
4.2 Global Gastrointestinal Forecasted Market Size by Type (2024-2029)
5 Gastrointestinal Breakdown Data by Application
5.1 Global Gastrointestinal Historic Market Size by Application (2018-2023)
5.2 Global Gastrointestinal Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Gastrointestinal Market Size (2018-2029)
6.2 North America Gastrointestinal Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Gastrointestinal Market Size by Country (2018-2023)
6.4 North America Gastrointestinal Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastrointestinal Market Size (2018-2029)
7.2 Europe Gastrointestinal Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Gastrointestinal Market Size by Country (2018-2023)
7.4 Europe Gastrointestinal Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Market Size (2018-2029)
8.2 Asia-Pacific Gastrointestinal Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Gastrointestinal Market Size by Region (2018-2023)
8.4 Asia-Pacific Gastrointestinal Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastrointestinal Market Size (2018-2029)
9.2 Latin America Gastrointestinal Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Gastrointestinal Market Size by Country (2018-2023)
9.4 Latin America Gastrointestinal Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Market Size (2018-2029)
10.2 Middle East & Africa Gastrointestinal Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Gastrointestinal Market Size by Country (2018-2023)
10.4 Middle East & Africa Gastrointestinal Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZenec
11.1.1 AstraZenec Company Detail
11.1.2 AstraZenec Business Overview
11.1.3 AstraZenec Gastrointestinal Introduction
11.1.4 AstraZenec Revenue in Gastrointestinal Business (2018-2023)
11.1.5 AstraZenec Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Gastrointestinal Introduction
11.2.4 Sanofi Revenue in Gastrointestinal Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Gastrointestinal Introduction
11.3.4 Bayer Revenue in Gastrointestinal Business (2018-2023)
11.3.5 Bayer Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Gastrointestinal Introduction
11.4.4 Pfizer Revenue in Gastrointestinal Business (2018-2023)
11.4.5 Pfizer Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Gastrointestinal Introduction
11.5.4 GlaxoSmithKline Revenue in Gastrointestinal Business (2018-2023)
11.5.5 GlaxoSmithKline Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Gastrointestinal Introduction
11.6.4 Teva Revenue in Gastrointestinal Business (2018-2023)
11.6.5 Teva Recent Development
11.7 Zeria（Tillotts）
11.7.1 Zeria（Tillotts） Company Detail
11.7.2 Zeria（Tillotts） Business Overview
11.7.3 Zeria（Tillotts） Gastrointestinal Introduction
11.7.4 Zeria（Tillotts） Revenue in Gastrointestinal Business (2018-2023)
11.7.5 Zeria（Tillotts） Recent Development
11.8 Perrigo
11.8.1 Perrigo Company Detail
11.8.2 Perrigo Business Overview
11.8.3 Perrigo Gastrointestinal Introduction
11.8.4 Perrigo Revenue in Gastrointestinal Business (2018-2023)
11.8.5 Perrigo Recent Development
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Detail
11.9.2 Boehringer Ingelheim Business Overview
11.9.3 Boehringer Ingelheim Gastrointestinal Introduction
11.9.4 Boehringer Ingelheim Revenue in Gastrointestinal Business (2018-2023)
11.9.5 Boehringer Ingelheim Recent Development
11.10 Purdue Pharma
11.10.1 Purdue Pharma Company Detail
11.10.2 Purdue Pharma Business Overview
11.10.3 Purdue Pharma Gastrointestinal Introduction
11.10.4 Purdue Pharma Revenue in Gastrointestinal Business (2018-2023)
11.10.5 Purdue Pharma Recent Development
11.11 C.B. Fleet
11.11.1 C.B. Fleet Company Detail
11.11.2 C.B. Fleet Business Overview
11.11.3 C.B. Fleet Gastrointestinal Introduction
11.11.4 C.B. Fleet Revenue in Gastrointestinal Business (2018-2023)
11.11.5 C.B. Fleet Recent Development
11.12 Abbott
11.12.1 Abbott Company Detail
11.12.2 Abbott Business Overview
11.12.3 Abbott Gastrointestinal Introduction
11.12.4 Abbott Revenue in Gastrointestinal Business (2018-2023)
11.12.5 Abbott Recent Development
11.13 Jiangzhong
11.13.1 Jiangzhong Company Detail
11.13.2 Jiangzhong Business Overview
11.13.3 Jiangzhong Gastrointestinal Introduction
11.13.4 Jiangzhong Revenue in Gastrointestinal Business (2018-2023)
11.13.5 Jiangzhong Recent Development
11.14 Xian-Janssen
11.14.1 Xian-Janssen Company Detail
11.14.2 Xian-Janssen Business Overview
11.14.3 Xian-Janssen Gastrointestinal Introduction
11.14.4 Xian-Janssen Revenue in Gastrointestinal Business (2018-2023)
11.14.5 Xian-Janssen Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details